DR. JOHN YIANNI, CEO

PhD in Biophysics, Founder, CEO, Board member of several medical device companies (Biocompatibles, Thermocore, Reverse Medical); launched first coated coronary stent in EU (exit to Abbott); Founder and Board member Reverse medical (exit to Medtronic), Partner, Earlybird Venture Capital Health Fund.

Mauro Turturici – R&D Manager Console Development

 Driven by innovation and fuelled by a genuine passion for advancing technology, Mauro Turturici is an experienced Product Development Engineer with a strong background in Electronics, Software and Medical Devices. With a PhD in Micro- and nano-electronic systems and a decade of experience in the medical devices industry, he has successfully contributed to numerous projects from concept to market, both as developer and project leader. Currently serving as an R&D Manager, he is constantly dedicated to pushing boundaries and creating groundbreaking solutions that improve lives and shape the healthcare innovations of the future.

Richard Meaney – R&D Manager Catheter Development

 With an MSc in Biomedical Engineering and 18 years broad experience in research, design and development of medical devices, Richard Meaney is our R&D Manager for Catheter Development. To this role he brings a wealth of expertise in leading teams and progressing innovative catheter-based technologies from concept generation right through to commercialisation, with start-ups to large FDA regulated medical device companies. Richard is passionate about new technologies and developing better tools for expert physicians and also has a deep-rooted drive to enhance quality of life and clinical outcomes for patients.  

Julie Humblet – Quality Manager

 As an engineer passionate for Medical Devices, with 10 years of experience in quality and operations in industry, Julie also has a Master’s Degree in Quality Assurance from University of Liège. Her experience includes design and development of Class III device, R&D and QA project coordination, the establishment and management of quality management systems ISO13485, auditing, ensuring compliance with applicable regulatory requirements as well as being the liaison to Notified Bodies and Health Authorities. With pragmatism and enthusiasm, she ensures that quality is transversely maintained at the heart of Cryo’s activities.

Danny Detiège – VP Clinical Affairs

 Danny has over 25 years of experience in clinical trials management, originally  in pharmaceuticals but more recently mainly in cardiovascular medical devices. He has held multiple positions in clinical strategy and clinical operations in both large and start-up medical device companies, as well as in CRO.

As Clinical Manager at Terumo Europe he was responsible for the coronary stent clinical program. At Medpace Medical Device CRO he managed the team running several global programs for medical device companies in several therapeutic areas. Prior to joining CryoTherapeutics he was Global Director Clinical Operations at Sequana Medical, successfully establishing the first clinical evidence for a new Class III device in volume overloaded heart failure.

Emmanuel Dagneaux | Finance & Administration Manager

 With a Masters’ in Business Engineering and Finance, Emmanuel is a seasoned finance professional with more than 25 years’ experience in the SME environment. He has assisted various companies in their growth by bringing skills such as financial expertise, M&A, fundraising, financing structuring, business development and people management. 

Prior to joining CryoTherapeutics , Emmanuel acted  as CFO for SME’s active in Energy, Green tech, and Telecom. He was financial controller in a biotech company and at PwC as senior auditor.


Board of Directors

Eric Brandt

Rainer Christine

Dr. Joachim Rautter

Karlheinz Schmelig

Florian Stinauer

ALFRED WONG

 

Update

CryoTherapeutics closes new €12.3 million financing round.

Find out more